by United Pompe | Jan 18, 2016 | News
Rescue of enzyme deficiency in embryonic diaphragm in a mouse
by United Pompe | Jan 18, 2016 | News
Long-Term Intravenous Treatment of Pompe Disease With Recombinant Human a-Glucosidase From Milk
by United Pompe | Jan 18, 2016 | News
Myozyme Produced at the 2000 L Bioreactor Scale to Receive Accelerated Approval Date: November 17, 2008 New PDUFA Date Set for February 28, 2009 Genzyme Corporation (Nasdaq: GENZ) today announced that the FDA plans an Accelerated Approval for Myozyme® (alglucosidase...
by United Pompe | Jan 18, 2016 | News
The Team Behind the Treatment by Marsha A. Green Yamila Jimenez is a 3-year-old walking miracle. She has Pompe (pronounced pom-PAY) disease, a rare genetic disease that means her body is unable to produce a vital enzyme needed to turn the sugar (glycogen) in her...
by United Pompe | Jan 18, 2016 | News
FDA Approves Genzyme’s Myozyme® for All Patients with Pompe Disease Date: April 28, 2006 Related Links Myozyme PI FDA Press Release Genzyme Corp. (Nasdaq: GENZ) announced today that the Food and Drug Administration has granted marketing approval for Myozyme®...
